Regenicin Inc.

Regenicin Inc. is a biotechnology company primarily focused on the development of regenerative cell therapies. The company aims to advance the medical treatment of damaged skin tissues through innovative products designed to grow human-like skin on patients with severe burns, chronic wounds, or other skin injuries. Regenicin Inc.'s core technology is centered around the use of autologous cell therapy, which utilizes a patient’s own cells to engineer a biological product that significantly reduces the risk of immune rejection. By targeting the healthcare and medical sectors, particularly hospitals and specialized clinics, Regenicin Inc. plays a crucial role in enhancing patient care outcomes and transforming the landscape of regenerative medicine. Headquartered in the United States, the company is committed to addressing unmet medical needs and contributing to the evolution of cell therapy solutions in the biomedical industry.